-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s Polypropylene Ampoule-Packaged Potassium Chloride Injection Has Passed Evaluation
Category:
发布时间：2023-11-10
【概要描述】
Recently, Shijiazhuang Sihua Pharmaceutical Group’s polypropylene ampoule–packaged potassium chloride injection (10 mL: 1.5 g) was approved by the National Medical Products Administration after passing the evaluation of quality and therapeutic equivalence for generic drugs. The group is the third domestic pharmaceutical company to achieve this milestone for this particular product.
Recently, the potassium chloride injection in polypropylene ampoule packaging (10 mL: 1.5 g) submitted by Shijiazhuang Sihua Pharmaceutical Group was approved by the National Medical Products Administration and has passed the evaluation of quality and therapeutic equivalence for generic drugs. The group is the third domestic pharmaceutical company to achieve this consistency evaluation for this particular product.
According to reports, potassium chloride injection is primarily used for the treatment and prevention of hypokalemia, as well as for the management of premature beats or rapid arrhythmias caused by digitalis toxicity.
In recent years, Shijiazhuang Sihua Pharmaceutical has steadfastly pursued an innovation-driven strategy, continuously enhancing its core competitiveness and consistently developing high-quality products to provide clinicians with more, safer, and more effective treatment options, thereby benefiting a broad patient population and contributing to the Healthy China initiative. To date, the group has achieved consistency evaluation—or is deemed to have achieved such evaluation—for a total of 65 drug varieties encompassing 85 dosage forms and strengths, maintaining a leading position in the industry for generic drug consistency evaluation.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091